-
- Matthew S. Davids
- All authors: Dana-Farber Cancer Institute, Boston, MA.
-
- Anthony Letai
- All authors: Dana-Farber Cancer Institute, Boston, MA.
説明
<jats:p> The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer. </jats:p>
収録刊行物
-
- Journal of Clinical Oncology
-
Journal of Clinical Oncology 30 (25), 3127-3135, 2012-09-01
American Society of Clinical Oncology (ASCO)
